Skip to main content

Table 2 Agreement table at the dichotomous level for valid, non-missing results

From: Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples

mCRC samples (n = 182)

therascreen KRAS RGQ PCR Kit

Idylla™ KRAS Mutation Test

KRAS mutation

KRAS Wild-type

Totals

KRAS Mutation

79

5

84

KRAS Wild-type

1

97

98

Totals

80

102

182

  1. Overall agreement between therascreen and Idylla™ platform for detection of KRAS mutations. mCRC metastatic colorectal cancer. KRAS Wild type = no mutation detected
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us